白蛋白在肝硬化患者中的应用现状

肝脏 ›› 2022, Vol. 27 ›› Issue (5): 511-513.

白蛋白在肝硬化患者中的应用现状

张舒茜, 赵红, 谢雯

首都医科大学附属北京地坛医院肝病中心

收稿日期:2022-04-28 出版日期:2022-05-31 发布日期:2022-07-13
通讯作者: 谢雯,Email:xiewen6218@163.com
基金资助:
首都卫生发展科研专项(2022-2-2174)

Received:2022-04-28 Online:2022-05-31 Published:2022-07-13

摘要/Abstract

摘要： 人血清白蛋白是人体血浆中最主要的蛋白质,参与调节多种机体功能。晚期肝硬化和失代偿期肝硬化患者,循环中“有效白蛋白”水平降低。因白蛋白具有渗透性和非渗透性方面的生理功能,白蛋白溶液被应用到肝病的各种并发症的治疗中。目前人白蛋白溶液已被推荐用于大量穿刺放液术、肝肾综合征、自发性细菌性腹膜炎患者的治疗。此外,研究表明白蛋白治疗可能对肝硬化合并高容量低钠血症、非自发性细菌性腹膜炎感染、脓毒症和肝性脑病的患者有潜在的益处。白蛋白在止血、肝硬化性心肌病、白蛋白透析的潜在应用需要更多的临床试验去验证。长期应用白蛋白可减少肝硬化相关并发症的发生,延缓疾病进程,提高患者生存质量。多个临床试验均提出,不同肝病及肝硬化阶段中白蛋白治疗的剂量、频率和疗程尚需探讨。我们希望未来能有更多的循证医学证据来指导肝硬化患者白蛋白的应用。

张舒茜, 赵红, 谢雯. 白蛋白在肝硬化患者中的应用现状[J]. 肝脏, 2022, 27(5): 511-513.

参考文献

[1] Jagdish RK,Maras JS,Sarin SK. Albumin in Advanced Liver Diseases: The Good and Bad of a Drug！Hepatology,2021,74:2848-2862.
[2] Bernardi M,Angeli P,Claria J,et al. Albumin in decompensated cirrhosis: new concepts and perspectives. Gut,2020,69:1127-1138.
[3] Bernardi M, Caraceni P. Novel perspectives in the management of decompensated cirrhosis. Nat Rev Gastroenterol Hepatol,2018,15:753-764.
[4] Vairappan B. Endothelial dysfunction in cirrhosis:Role of inflammation and oxidative stress.World J Hepatol,2015,7:443-459.
[5] Jalan R,Bernardi M. Effective albumin concentration and cirrhosis mortality: from concept to reality. J Hepatol,2013,59:918-920.
[6] Arora V,Vijayaraghavan R,Maiwall R,et al.Paracentesis-Induced Circulatory Dysfunction With Modest-Volume Paracentesis Is Partly Ameliorated by Albumin In fusion in Acute-on-Chronic Liver Failure. Hepatology,2020,72:1043-1055.
[7] Maiwall R,Pasupuleti SSR,Bihari C,et al. Incidence,Risk Factors,and Outcomes of Transition of Acute Kidney Injury to Chronic Kidney Disease in Cirrhosis: A Prospective Cohort Study.Hepatology,2020,71:1009-1022.
[8] Aithal G,Palaniyappan N,China L,et al.Guidelines on the management of ascites in cirrhosis.Gut,2021,70:9-29.
[9] Alukal JJ,John S,Thuluvath PJ. Hyponatremiain Cirrhosis:An Update. Am J Gastroenterol,2020,115:1775-1785.
[10] Caraceni P, Riggio O, Angeli P, et al. Long-term albumin administration in decompensated cirrhosis(ANSWER):an open-label randomized trial. Lancet, 2018,391:2417-2429.
[11] China L,Freemantle N,Forrest E,et al. A Randomized Trial of Albumin Infusions in Hospitalized Patients with Cirrhosis. N Engl J Med,2021,384:808-817.
[12] China L,Freemantle N,Forrest E,et al. A Randomized Trial of Albumin Infusions in Hospitalized Patients with Cirrhosis. N Engl J Med,2021,384:808-817.
[13] Thevenot T, Bureau C, Oberti F, et al. Effect of albuminin cirrhotic patients with infection other than spontaneous bacterial peritonitis. A randomized trial. J Hepatol,2015,62:822-830.
[14] Fernandez J,Angeli P,Trebicka J,et al. Efficacy of Albumin Treatment for Patients with Cirrhosis and Infections Unrelated to Spontaneous Bacterial Peritonitis. Clin Gastroenterol Hepatol,2020,18:963-973.
[15] Philips CA,Maiwall R,Sharma MK,et al. Comparison of 5%human albumin and normal saline for fluid resuscitation in sepsis induced hypotension among patients with cirrhosis(FRISC study):a randomized controlled trial. Hepatol Int,2021,15:983-994.
[16] Maiwall R,Maras JS,Nayak SL,et al. Liver dialysis in acute-on-chronic liver failure:current and future perspectives. Hepatol Int,2014,8 Suppl2:505-513.
[17] Fernandez J,Claria J,Amoros A,et al. Effects of Albumin Treatment on Systemic and Portal Hemodynamics and Systemic Inflammation in Patients With Decompensated Cirrhosis. Gastroenterology,2019,157:149-162.
[18] Caraceni P, Tufoni M, Zaccherini G, et al. On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites. J Hepatol,2021,74(2):340-349.